Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Research and Development

Human HealthOasmia is developing the next generation of drugs with focus on oncology.

Further reading »

About Oasmia

Animal HealthOasmia is a pharmaceutical company in Uppsala, Sweden with one approved product in Russia and one conditionally approved in the USA.

Further reading »

The Share

Latest News

Notice convening the Annual General Meeting of Shareholders in Oasmia Pharmaceutical AB

August 26 2016
The shareholders of Oasmia Pharmaceutical AB (publ), 556332-6676, are invited to participate in the Annual General Meeting to be held on Monday, September 26, 2016 at 3 p.m. at Vallongatan 1, Uppsala, Sweden. The registration will start at 2.30 p.m.
Further reading »

The Oasmia Pharmaceutical Annual Report is now published

July 8 2016
Further reading »

Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000

June 10 2016
Uppsala, Sweden, June 10, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 42,000,000 with an interest rate of 8.5 per cent per year directed to and placed with a limited group of investors identified by Stockholm Corporate Finance AB (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 42,000,000 before transaction related costs.
Further reading »